Cannabinoid receptors in the central nervous system: Their signaling and roles in disease

Frontiers in Cellular Neuroscience

Volumn 10, Issue , 2017, Pages

  Kendall, Debra A ^a   Yudowski, Guillermo A ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

CB1 receptors; Endocannabinoid system; Neuromodulation; Signaling; 9 THC

Indexed keywords

BETA ARRESTIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYTOKINE; DRONABINOL; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; LIGAND; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2;

ALZHEIMER DISEASE; ANTINOCICEPTION; ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM SIGNALING; CENTRAL NERVOUS SYSTEM DISEASE; DYSPHORIA; HUMAN; HUNTINGTON CHOREA; HYPOTHERMIA; MICROGLIA; MULTIPLE SCLEROSIS; NEOCORTEX; NERVE CELL PLASTICITY; NEUROMODULATION; NONHUMAN; PARADOXICAL PULSE; RISK FACTOR; SIGNAL TRANSDUCTION; TRAUMATIC BRAIN INJURY; UPREGULATION; WNT SIGNALING PATHWAY;

EID: 85012107882     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2016.00294     Document Type: Article

References (130)

1. Ahn, K. H., Mahmoud, M. M., Shim, J.-Y., and Kendall, D. A. (2013). Distinct roles of P-arrestin 1 and P-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J. Biol. Chem. 288, 9790-9800. doi:10.1074/jbc.M112.438804
2. Arévalo-Martín, A., Vela, J. M., Molina-Holgado, E., Borrell, J., and Guaza, C. (2003). Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 23, 2511-2516.
3. Aso, E., and Ferrer, I. (2014). Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. Front. Pharmacol. 5:37. doi:10.3389/fphar.2014.00037
4. Atwood, B. K., Lopez, J., Wager-Miller, J., Mackie, K., and Straiker, A. (2011). Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2 and N18 cell lines as revealed by microarray analysis. BMC Genomics 12:14. doi:10.1186/1471-2164-12-14
5. Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Huffman, J. W., et al. (2000). Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404, 84-87. doi:10.1038/35003583
6. Bilkei-Gorzo, A. (2012). The endocannabinoid system in normal and pathological brain ageing. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367, 3326-3341. doi:10.1098/rstb.2011.0388
7. Blâzquez, C., Chiarlone, A., Bellocchio, L., Resel, E., Pruunsild, P., García-Rincón, D., et al. (2015). The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. Cell Death Differ. 22,1618-1629. doi:10.1038/cdd.2015.11
8. Bosier, B., Muccioli, G. G., Hermans, E., and Lambert, D. M. (2010). Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem. Pharmacol. 80, 1-12. doi:10.1016/j.bcp.2010.02.013
9. Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., et al. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1: evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272, 22330-22339. doi:10.1074/jbc.272.35.22330
10. Brailoiu, G. C., Deliu, E., Marcu, J., Hoffman, N. E., Console-Bram, L., Zhao, P., et al. (2014). Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors. Biochemistry 53, 4990-4999. doi:10.1021/bi500632a
11. Brailoiu, G. C., Oprea, T. I., Zhao, P., Abood, M. E., and Brailoiu, E. (2011). Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide. J. Biol. Chem. 286, 29166-29174. doi:10.1074/jbc.M110.217463
12. Breivogel, C. S., Lambert, J. M., Gerfin, S., Huffman, J. W., and Razdan, R. K. (2008). Sensitivity to 09-tetrahydrocannabinol is selectively enhanced in beta-arrestin2-/-mice. Behav. Pharmacol. 19, 298-307. doi:10.1097/FBP.0b013e328308f1e6
13. Breivogel, C. S., and Vaghela, M. S. (2015). The effects of beta-arrestin1 deletion on acute cannabinoid activity, brain cannabinoid receptors and tolerance to cannabinoids in mice. J. Recept. Signal Transduct. Res. 35, 98-106. doi:10.3109/10799893.2014.1003659
14. Brenneisen, R. (2007). “Chemistry and analysis of phytocannabinoids and other cannabis constituents,” in Forensic Science And Medicine, ed. M. A. ElSohly (Totowa, NJ: Humana Press), 17-49.
15. Butcher, A. J., Prihandoko, R., Kong, K. C., McWilliams, P., Edwards, J. M., Bottrill, A., et al. (2011). Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code. J. Biol. Chem. 286, 11506-11518. doi:10.1074/jbc.M110.154526
16. Campbell, V. A., and Gowran, A. (2007). Alzheimer’s disease; taking the edge off with cannabinoids? Br. J. Pharmacol. 152,655-662. doi:10.1038/sj.bjp.0707446
17. Castillo, P. E., Younts, T. J., Châvez, A. E., and Hashimotodani, Y. (2012). Endocannabinoid signaling and synaptic function. Neuron 76, 70-81. doi:10.1016/j.neuron.2012.09.020
18. Chevaleyre, V., Takahashi, K. A., and Castillo, P. E. (2006). Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 29,37-76. doi:10.1146/annurev.neuro.29.051605.112834
19. Croxford, J. L. (2003). Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17, 179-202. doi:10.2165/00023210-200317030-00004
20. Delgado-Peraza, F., Ahn, K. H., Nogueras-Ortiz, C., Mungrue, I. N., Mackie, K., Kendall, D. A., et al. (2016). Mechanisms of biased 18-arrestin-mediated signaling downstream from the cannabinoid 1 receptor. Mol. Pharmacol. 89, 618-629. doi:10.1124/mol.115.103176
21. Demuth, D. G., and Molleman, A. (2006). Cannabinoid signalling. Life Sci. 78, 549-563. doi:10.1016/j.lfs.2005.05.055
22. Derkinderen, P., Ledent, C., Parmentier, M., and Girault, J. A. (2001). Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J. Neurochem. 77,957-960. doi:10.1046/j.1471-4159.2001.00333.x
23. Dowie, M. J., Howard, M. L., Nicholson, L. F. B., Faull, R. L. M., Hannan, A. J., and Glass, M. (2010). Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington’s disease transgenic mice. Neuroscience 170, 324-336. doi:10.1016/j.neuroscience.2010.06.056
24. Dudok, B., Barna, L., Ledri, M., Szabó, S. I., Szabadits, E., Pintér, B., et al. (2015). Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling. Nat. Neurosci. 18, 75-86. doi:10.1038/nn.3892
25. Eldeeb, K., Leone-Kabler, S., and Howlett, A. C. (2016). CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function. J. Basic Clin. Physiol. Pharmacol. 27, 311-322. doi:10.1515/jbcpp-2015-0096
26. Esposito, G., De Filippis, D., Carnuccio, R., Izzo, A. A., and Iuvone, T. (2006). The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells. J. Mol. Med. (Berl) 84, 253-258. doi:10.1007/s00109-005-0025-1
27. Fernândez-Ruiz, J., Moreno-Martet, M., Rodríguez-Cueto, C., Palomo-Garo, C., Gómez-Cañas, M., Valdeolivas, S., et al. (2011). Prospects for cannabinoid therapies in basal ganglia disorders. Br. J. Pharmacol. 163, 1365-1378. doi:10.1111/j.1476-5381.2011.01365.x
28. Flores-Otero, J., Ahn, K. H., Delgado-Peraza, F., Mackie, K., Kendall, D. A., and Yudowski, G. A. (2014). Ligand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1. Nat. Commun. 5:4589. doi:10.1038/ncomms5589
29. Fonseca, B. M., Costa, M. A., Almada, M., Correia-da-Silva, G., and Teixeira, N. A. (2013). Endogenous cannabinoids revisited: a biochemistry perspective. Prostaglandins Other Lipid Mediat. 102-103, 13-30. doi:10.1016/j.prostaglandins.2013.02.002
30. Fride, E., Perchuk, A., Hall, F. S., Uhl, G. R., and Onaivi, E. S. (2006). Behavioral methods in cannabinoid research. Methods Mol. Med. 123, 269-290. doi:10.1385/1-59259-999-0:269
31. Fu, W., and Taylor, B. K. (2015). Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neurosci. Lett. 595, 1-6. doi:10.1016/j.neulet.2015.04.002
32. Glass, M., Dragunow, M., and Faull, R. L. M. (2000). The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience 97, 505-519. doi:10.1016/s0306-4522(00)00008-7
33. Glass, M., and Felder, C. C. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17, 5327-5333.
34. Glass, M., and Northup, J. K. (1999). Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 56,1362-1369.
35. Gruenbaum, S. E., Zlotnik, A., Gruenbaum, B. F., Hersey, D., and Bilotta, F. (2016). Pharmacologic neuroprotection for functional outcomes after traumatic brain injury: a systematic review of the clinical literature. CNS Drugs 30, 791-806. doi:10.1007/s40263-016-0355-2
36. Guo, J., and Ikeda, S. R. (2004). Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. Mol. Pharmacol. 65, 665-674. doi:10.1124/mol.65.3.665
37. Gyombolai, P., Tóth, A. D., Timâr, D., Turu, G., and Hunyady, L. (2015). Mutations in the “DRY” motif of the CB1 cannabinoid receptor result in biased receptor variants. J. Mol. Endocrinol. 54, 75-89. doi:10.1530/JME-14-0219
38. Hart, S., Fischer, O. M., and Ullrich, A. (2004). Cannabinoids induce cancer cell proliferation via tumor necrosis factor a-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 64, 1943-1950. doi:10.1158/0008-5472.can-03-3720
39. Heifets, B. D., and Castillo, P. E. (2009). Endocannabinoid signaling and long-term synaptic plasticity. Annu. Rev. Physiol. 71, 283-306. doi:10.1146/annurev.physiol.010908.163149
40. Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., de Costa, B. R., and Rice, K. C. (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563-583.
41. Howlett, A. C. (2005). Cannabinoid receptor signaling. Handb. Exp. Pharmacol. 168, 53-79. doi:10.1007/3-540-26573-2_2
42. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., et al. (2002). International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161-202. doi:10.1124/pr.54.2.161
43. Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., and Porrino, L. J. (2004). Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47, 345-358. doi:10.1016/j.neuropharm.2004.07.030
44. Hua, T., Vemuri, K., Pu, M., Qu, L., Won Han, G., Wu, Y., et al. (2016). Crystal structure of the human cannabinoid receptor CB1. Cell 167, 750.e14-762.e14. doi:10.1016/j.cell.2016.10.004
45. Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L., Nelson, R. A., Moolchan, E. T., et al. (2001). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry 58, 322-328. doi:10.1001/archpsyc.58.4.322
46. Irannejad, R., and von Zastrow, M. (2014). GPCR signaling along the endocytic pathway. Curr. Opin. Cell Biol. 27, 109-116. doi:10.1016/j.ceb.2013.10.003
47. Jackson, S. J., Pryce, G., Diemel, L. T., Cuzner, M. L., and Baker, D. (2005). Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 134, 261-268. doi:10.1016/j.neuroscience.2005.02.045
48. Jiang, W., Zhang, Y., Xiao, L., Van Cleemput, J., Ji, S. P., Bai, G., et al. (2005). Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic-and antidepressant-like effects. J. Clin. Invest. 115, 3104-3116. doi:10.1172/jci25509
49. Jin, W., Brown, S., Roche, J. P., Hsieh, C., Celver, J. P., Kovoor, A., et al. (1999). Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J. Neurosci. 19, 3773-3780.
50. Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., and Watanabe, M. (2009). Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 89, 309-380. doi:10.1152/physrev.00019.2008
51. Katona, I., and Freund, T. F. (2012). Multiple functions of endocannabinoid signaling in the brain. Annu. Rev. Neurosci. 35,529-558. doi:10.1146/annurev-neuro-062111-150420
52. Kenakin, T. (2004). Principles: receptor theory in pharmacology. Trends Pharmacol. Sci. 25, 186-192. doi:10.1016/j.tips.2004.02.012
53. Klein, T. W. (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5, 400-411. doi:10.1038/nri1602
54. Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., and Denovan-Wright, E. M. (2016). Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease. Mol. Pharmacol. 89,364-375. doi:10.1124/mol.115.101980
55. Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., Dupré, D. J., and Denovan-Wright, E. M. (2014). Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. J. Biol. Chem. 289, 24845-24862. doi:10.1074/jbc.m114.557025
56. Leterrier, C., Bonnard, D., Carrel, D., Rossier, J., and Lenkei, Z. (2004). Constitutive endocytic cycle of the CB1 cannabinoid receptor. J. Biol. Chem. 279, 36013-36021. doi:10.1074/jbc.M403990200
57. Leterrier, C., Lainé, J., Darmon, M., Boudin, H., Rossier, J., and Lenkei, Z. (2006). Constitutive activation drives compartment-selective endocytosis and axonal targeting of type 1 cannabinoid receptors. J. Neurosci. 26, 3141-3153. doi:10.1523/JNEUROSCI.5437-05.2006
58. Liggett, S. B. (2011). Phosphorylation barcoding as a mechanism of directing GPCR signaling. Sci. Signal. 4:pe36. doi:10.1126/scisignal.2002331
59. Little, P. J., Compton, D. R., Johnson, M. R., Melvin, L. S., and Martin, B. R. (1988). Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther. 247,1046-1051.
60. Liu, C. S., Chau, S. A., Ruthirakuhan, M., Lanctôt, K. L., and Herrmann, N. (2015). Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease. CNS Drugs 29, 615-623. doi:10.1007/s40263-015-0270-y
61. Lopez-Rodriguez, A. B., Siopi, E., Finn, D. P., Marchand-Leroux, C., Garcia-Segura, L. M., Jafarian-Tehrani, M., et al. (2015). CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice. Cereb. Cortex 25, 35-45. doi:10.1093/cercor/bht202
62. Lyga, S., Volpe, S., Werthmann, R. C., Götz, K., Sungkaworn, T., Lohse, M. J., et al. (2016). Persistent cAMP signaling by internalized LH receptors in ovarian follicles. Endocrinology 157, 1613-1621. doi:10.1210/en.2015-1945
63. Maccarrone, M., Guzmân, M., Mackie, K., Doherty, P., and Harkany, T. (2014). Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. Nat. Rev. Neurosci. 15, 786-801. doi:10.1038/nrn3846
64. Mackie, K. (2006). Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength. Int. J. Obes. (Lond). 30, S19-S23. doi:10.1038/sj.ijo.0803273
65. Mackie, K. (2008). Cannabinoid receptors: where they are and what they do. J. Neuroendocrinol. 20, 10-14. doi:10.1111/j.1365-2826.2008.01671.x
66. Mackie, K., Lai, Y., Westenbroek, R., and Mitchell, R. (1995). Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15, 6552-6561.
67. Maldonado, R., Valverde, O., and Berrendero, F. (2006). Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 29, 225-232. doi:10.1016/j.tins.2006.01.008
68. Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D., Corder, G., et al. (2016). Structure-based discovery of opioid analgesics with reduced side effects. Nature 537,185-190. doi:10.1038/nature19112
69. Maresz, K., Pryce, G., Ponomarev, E. D., Marsicano, G., Croxford, J. L., Shriver, L. P., et al. (2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 13, 492-497. doi:10.1038/nm1561
70. Maroso, M., Szabo, G. G., Kim, H. K., Alexander, A., Bui, A. D., Lee, S.-H., et al. (2016). Cannabinoid control of learning and memory through HCN channels. Neuron 89, 1059-1073. doi:10.1016/j.neuron.2016.01.023
71. Marsicano, G., and Kuner, R. (2008). “Anatomical distribution of receptors, ligands and enzymes in the brain and in the spinal cord: circuitries and neurochemistry,” in Cannabinoids and The Brain, ed. A. Köfalvi (Boston, MA: Springer US), 161-201.
72. Marsicano, G., and Lutz, B. (2006). Neuromodulatory functions of the endocannabinoid system. J. Endocrinol. Invest. 29, 27-46.
73. Martini, L., Waldhoer, M., Pusch, M., Kharazia, V., Fong, J., Lee, J. H., et al. (2007). Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1. FASEB J. 21, 802-811. doi:10.1096/fj.06-7132com
74. Di Marzo, V. (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov. 7, 438-455. doi:10.1038/nrd2553
75. Di Marzo, V., Stella, N., and Zimmer, A. (2014). Endocannabinoid signalling and the deteriorating brain. Nat. Rev. Neurosci. 16, 30-42. doi:10.1038/nrn3876
76. McCaw, E. A., Hu, H., Gomez, G. T., Hebb, A. L. O., Kelly, M. E. M., and Denovan-Wright, E. M. (2004). Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington’s disease transgenic mice. Eur. J. Biochem. 271, 4909-4920. doi:10.1111/j.1432-1033.2004.04460.x
77. McDonald, N. A., Henstridge, C. M., Connolly, C. N., and Irving, A. J. (2007). An essential role for constitutive endocytosis, but not activity, in the axonal targeting of the CB1 cannabinoid receptor. Mol. Pharmacol. 71, 976-984. doi:10.1124/mol.106.029348
78. Mechoulam, R., and Parker, L. A. (2013). The endocannabinoid system and the brain. Annu. Rev. Psychol. 64, 21-47. doi:10.1146/annurev-psych-113011-143739
79. Mechoulam, R., and Shohami, E. (2007). Endocannabinoids and traumatic brain injury. Mol. Neurobiol. 36, 68-74. doi:10.1007/s12035-007-8008-6
80. Mievis, S., Blum, D., and Ledent, C. (2011). Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol. Dis. 42,524-529. doi:10.1016/j.nbd.2011.03.006
81. Mukhopadhyay, S., and Howlett, A. C. (2001). CB1 receptor-G protein association. Subtype selectivity is determined by distinct intracellular domains. Eur. J. Biochem. 268, 499-505. doi:10.1046/j.1432-1327.2001.01810.x
82. Mulder, J., Zilberter, M., Pasquaré, S. J., Alpâr, A., Schulte, G., Ferreira, S. G., et al. (2011). Molecular reorganization of endocannabinoid signalling in Alzheimer’s disease. Brain 134, 1041-1060. doi:10.1093/brain/awr046
83. Multiple sclerosis in adults: management | 1-recommendations | Guidance and guidelines | NICE. (2014). NICE. Available online at: https://www.nice.org.uk/guidance/CG186
84. Nguyen, P. T., Schmid, C. L., Raehal, K. M., Selley, D. E., Bohn, L. M., and Sim-Selley, L. J. (2012). β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biol. Psychiatry 71, 714-724. doi:10.1016/j.biopsych.2011.11.027
85. Nie, J., and Lewis, D. L. (2001). Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration. J. Neurosci. 21, 8758-8764.
86. Nobles, K. N., Xiao, K., Ahn, S., Shukla, A. K., Lam, C. M., Rajagopal, S., et al. (2011). Distinct phosphorylation sites on the 02-adrenergic receptor establish a barcode that encodes differential functions of P-arrestin. Sci. Signal. 4:ra51. doi:10.1126/scisignal.2001707
87. Nogueras-Ortiz, C., and Yudowski, G. A. (2016). The multiple waves of cannabinoid 1 receptor signaling. Mol. Pharmacol. 90, 620-626. doi:10.1124/mol.116.104539
88. Notcutt, W., Langford, R., Davies, P., Ratcliffe, S., and Potts, R. (2012). A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult. Scler. 18, 219-228. doi:10.1177/1352458511419700
89. Otero-Romero, S., Sastre-Garriga, J., Comi, G., Hartung, H.-P., Soelberg Sørensen, P., Thompson, A. J., et al. (2016). Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult. Scler. 22, 1386-1396. doi:10.1177/1352458516643600
90. Ozaita, A., Puighermanal, E., and Maldonado, R. (2007). Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J. Neurochem. 102, 1105-1114. doi:10.1111/j.1471-4159.2007.04642.x
91. Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C., Resel, E., et al. (2009). Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain 132, 3152-3164. doi:10.1093/brain/awp239
92. Pamplona, F. A., Ferreira, J., Menezes de Lima, O. Jr., Duarte, F. S., Bento, A. F., Forner, S., et al. (2012). Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc. Natl. Acad. Sci. U S A 109, 21134-21139. doi:10.1073/pnas.1202906109
93. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanuš, L., Breuer, A., Mechoulam, R., et al. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527-531. doi:10.1038/35097089
94. Park, P. S.-H. S.-H., Lodowski, D. T., and Palczewski, K. (2008). Activation of G protein-coupled receptors: beyond two-state models and tertiary conformational changes. Annu. Rev. Pharmacol. Toxicol. 48, 107-141. doi:10.1146/annurev.pharmtox.48.113006.094630
95. Parsons, L. H., and Hurd, Y. L. (2015). Endocannabinoid signalling in reward and addiction. Nat. Rev. Neurosci. 16, 579-594. doi:10.1038/nrn4004
96. Perez, D. M., and Karnik, S. S. (2005). Multiple signaling states of G-protein-coupled receptors. Pharmacol. Rev. 57, 147-161. doi:10.1124/pr.57.2.2
97. Pertwee, R. G. (2007). Cannabinoids and multiple sclerosis. Mol. Neurobiol. 36, 45-59. doi:10.1007/s12035-007-0005-2
98. Pertwee, R. G. (2015). Endocannabinoids and their pharmacological actions. Handb. Exp. Pharmacol. 231, 1-37. doi:10.1007/978-3-319-20825-1_1
99. Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., et al. (2010). International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62, 588-631. doi:10.1124/pr.110.003004
100. Prihandoko, R., Alvarez-Curto, E., Hudson, B. D., Butcher, A. J., Ulven, T., Miller, A. M., et al. (2016). Distinct phosphorylation clusters determine the signaling outcome of free fatty acid receptor 4/G protein-coupled receptor 120. Mol. Pharmacol. 89, 505-520. doi:10.1124/mol.115.101949
101. Pryce, G., Ahmed, Z., Hankey, D. J. R., Jackson, S. J., Croxford, J. L., Pocock, J. M., et al. (2003). Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126, 2191-2202. doi:10.1093/brain/awg224
102. Ramírez, B. G., Blâzquez, C., Gómez del Pulgar, T. G., Guzmân, M., and de Ceballos, M. L. (2005). Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25, 1904-1913. doi:10.1523/JNEUROSCI.4540-04.2005
103. Roche, J. P., Bounds, S., Brown, S., and Mackie, K. (1999). A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization. Mol. Pharmacol. 56, 611-618. doi:10.1124/mol.56.3.611
104. Rog, D. J. (2010). Cannabis-based medicines in multiple sclerosis-a review of clinical studies. Immunobiology 215, 658-672. doi:10.1016/j.imbio.2010.03.009
105. Rozenfeld, R. (2011). Type I cannabinoid receptor trafficking: all roads lead to lysosome. Traffic 12, 12-18. doi:10.1111/j.1600-0854.2010.01130.x
106. Rozenfeld, R., and Devi, L. A. (2008). Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J. 22, 2311-2322. doi:10.1096/fj.07-102731
107. Rueda, D., Galve-Roperh, I., Haro, A., and Guzmân, M. (2000). The CB1 cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol. Pharmacol. 58, 814-820. doi:10.1124/mol.58.4.814
108. Sagredo, O., García-Arencibia, M., de Lago, E., Finetti, S., Decio, A., and Fernândez-Ruiz, J. (2007). Cannabinoids and neuroprotection in basal ganglia disorders. Mol. Neurobiol. 36, 82-91. doi:10.1007/s12035-007-0004-3
109. Saito, V. M., Rezende, R. M., and Teixeira, A. L. (2012). Cannabinoid modulation of neuroinflammatory disorders. Curr. Neuropharmacol. 10, 159-166. doi:10.2174/157015912800604515
110. Scotter, E. L., Abood, M. E., and Glass, M. (2010). The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br. J. Pharmacol. 160, 480-498. doi:10.1111/j.1476-5381.2010.00735.x
111. Shohami, E., Cohen-Yeshurun, A., Magid, L., Algali, M., and Mechoulam, R. (2011). Endocannabinoids and traumatic brain injury. Br. J. Pharmacol. 163, 1402-1410. doi:10.1111/j.1476-5381.2011.01343.x
112. Soltesz, I., Alger, B. E., Kano, M., Lee, S.-H., Lovinger, D. M., Ohno-Shosaku, T., et al. (2015). Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy. Nat. Rev. Neurosci. 16, 264-277. doi:10.1038/nrn3937
113. Stempel, A. V., Stumpf, A., Zhang, H. Y., Özdogan, T., Pannasch, U., Theis, A. K., et al. (2016). Cannabinoid type 2 receptors mediate a cell type-specific plasticity in the hippocampus. Neuron 90, 795-809. doi:10.1016/j.neuron.2016.03.034
114. Straiker, A., and Mackie, K. (2005). Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J. Physiol. 569, 501-517. doi:10.1113/jphysiol.2005.091918
115. Straiker, A., Wager-Miller, J., Hutchens, J., and Mackie, K. (2012). Differential signalling in human cannabinoid CB1 receptors and their splice variants in autaptic hippocampal neurones. Br. J. Pharmacol. 165, 2660-2671. doi:10.1111/j.1476-5381.2011.01744.x
116. Stumm, C., Hiebel, C., Hanstein, R., Purrio, M., Nagel, H., Conrad, A., et al. (2013). Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. Neurobiol. Aging 34, 2574-2584. doi:10.1016/j.neurobiolaging.2013.05.027
117. Thomsen, A. R. B., Plouffe, B., Cahill, T. J. III., Shukla, A. K., Tarrasch, J. T., Dosey, A. M., et al. (2016). GPCR-G protein-p-arrestin super-complex mediates sustained G protein signaling. Cell 166, 907-919. doi:10.1016/j.cell.2016.07.004
118. Trazzi, S., Steger, M., Mitrugno, V. M., Bartesaghi, R., and Ciani, E. (2010). CB1 cannabinoid receptors increase neuronal precursor proliferation through AKT/glycogen synthase kinase-30/β-catenin signaling. J. Biol. Chem. 285, 10098-10109. doi:10.1074/jbc.M109.043711
119. Twitchell, W., Brown, S., and Mackie, K. (1997). Cannabinoids inhibit N-and P/Q-type calcium channels in cultured rathippocampal neurons. J. Neurophysiol. 78, 43-50.
120. Valdeolivas, S., Satta, V., Pertwee, R. G., Fernândez-Ruiz, J., and Sagredo, O. (2012). Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB1 and CB2 receptors. ACS Chem. Neurosci. 3, 400-406. doi:10.1021/cn200114w
121. Vallée, M., Vitiello, S., Bellocchio, L., Hébert-Chatelain, E., Monlezun, S., Martin-Garcia, E., et al. (2014). Pregnenolone can protect the brain from cannabis intoxication. Science 343, 94-98. doi:10.1126/science.1243985
122. Varga, E. V., Georgieva, T., Tumati, S., Alves, I., Salamon, Z., Tollin, G., et al. (2008). Functional selectivity in cannabinoid signaling. Curr. Mol. Pharmacol. 1, 273-284. doi:10.2174/1874-470210801030273
123. Varvel, S. A., Martin, B. R., and Lichtman, A. H. (2007). Lack of behavioral sensitization after repeated exposure to THC in mice and comparison to methamphetamine. Psychopharmacology (Berl) 193, 511-519. doi:10.1007/s00213-007-0811-2
124. Wade, D. T., Collin, C., Stott, C., and Duncombe, P. (2010). Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult. Scler. 16, 707-714. doi:10.1177/1352458510367462
125. Wilson, R. I., and Nicoll, R. A. (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588-592. doi:10.1038/35069076
126. Wu, D.-F., Yang, L.-Q., Goschke, A., Stumm, R., Brandenburg, L.-O., Liang, Y.-J., et al. (2008). Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors. J. Neurochem. 104, 1132-1143. doi:10.1111/j.1471-4159.2007.05063.x
127. Xi, Z.-X., Peng, X.-Q., Li, X., Song, R., Zhang, H.-Y., Liu, Q.-R., et al. (2011). Brain cannabinoid CB2 receptors modulate cocaine’s actions in mice. Nat. Neurosci. 14, 1160-1166. doi:10.1038/nm.2483
128. Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., and Sheng, M. (2016). TREM2 binds to apolipoproteins, including APOE and CLU/APOJ and thereby facilitates uptake of amyloid-P by microglia. Neuron 91, 328-340. doi:10.1016/j.neuron.2016.06.015
129. Zhang, H.-Y., Gao, M., Shen, H., Bi, G.-H., Yang, H.-J., Liu, Q.-R., et al. (2016). Expression of functional cannabinoid CB2 receptor in VTA dopamine neurons in rats. Addict. Biol. doi:10.1111/adb.12367[Epubaheadofprint].
130. Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., and Bonner, T. I. (1999). Increased mortality, hypoactivity and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA 96,5780-5785. doi:10.1073/pnas.96.10.5780